BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents

X. B. Shi, P. H. Gumerlock, J. T. Muenzer, Ralph W deVere White

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prostate cancer (CaP) is the most commonly diagnosed cancer of aging men and the second leading cause of male cancer death in the United States. At present, no effective therapy is available for treating hormone independent CaP. Since Bcl2 is believed to play a role in protecting CaP cells from apoptosis, we investigated the effects of down-regulating Bcl2 expression on CaP cells. Genetically engineered LNCaP sublines were established by stably transfecting LNCaP cells with BCL2 antisense (BCL2-AS) transcript-expressing plasmids. Western blotting analysis showed that intracellular Bcl2 protein was decreased by 50-60% in BCL2-AS-transfected LNCaP cells. Expression of the antisense transcripts resulted in 50% growth inhibition of LNCaP cells in response to androgen withdrawal and markedly sensitized these cells to Adriamycin-induced apoptosis. These results suggest that down-regulation of Bcl2 protein using BCL2-AS transcripts could be exploited for improved treatment of advanced CaP.

Original languageEnglish (US)
Pages (from-to)421-429
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Volume16
Issue number5
StatePublished - 2001

Fingerprint

Prostatic Neoplasms
Apoptosis
Proto-Oncogene Proteins c-bcl-2
Doxorubicin
Androgens
Neoplasms
Plasmids
Down-Regulation
Western Blotting
Hormones
Therapeutics
Growth
Proteins

Keywords

  • Apoptosis
  • Bcl2
  • BCL2-AS
  • LNCaP
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents. / Shi, X. B.; Gumerlock, P. H.; Muenzer, J. T.; deVere White, Ralph W.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 16, No. 5, 2001, p. 421-429.

Research output: Contribution to journalArticle

@article{215d9d3a45f9440b95040657a21f2409,
title = "BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents",
abstract = "Prostate cancer (CaP) is the most commonly diagnosed cancer of aging men and the second leading cause of male cancer death in the United States. At present, no effective therapy is available for treating hormone independent CaP. Since Bcl2 is believed to play a role in protecting CaP cells from apoptosis, we investigated the effects of down-regulating Bcl2 expression on CaP cells. Genetically engineered LNCaP sublines were established by stably transfecting LNCaP cells with BCL2 antisense (BCL2-AS) transcript-expressing plasmids. Western blotting analysis showed that intracellular Bcl2 protein was decreased by 50-60{\%} in BCL2-AS-transfected LNCaP cells. Expression of the antisense transcripts resulted in 50{\%} growth inhibition of LNCaP cells in response to androgen withdrawal and markedly sensitized these cells to Adriamycin-induced apoptosis. These results suggest that down-regulation of Bcl2 protein using BCL2-AS transcripts could be exploited for improved treatment of advanced CaP.",
keywords = "Apoptosis, Bcl2, BCL2-AS, LNCaP, Prostate cancer",
author = "Shi, {X. B.} and Gumerlock, {P. H.} and Muenzer, {J. T.} and {deVere White}, {Ralph W}",
year = "2001",
language = "English (US)",
volume = "16",
pages = "421--429",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents

AU - Shi, X. B.

AU - Gumerlock, P. H.

AU - Muenzer, J. T.

AU - deVere White, Ralph W

PY - 2001

Y1 - 2001

N2 - Prostate cancer (CaP) is the most commonly diagnosed cancer of aging men and the second leading cause of male cancer death in the United States. At present, no effective therapy is available for treating hormone independent CaP. Since Bcl2 is believed to play a role in protecting CaP cells from apoptosis, we investigated the effects of down-regulating Bcl2 expression on CaP cells. Genetically engineered LNCaP sublines were established by stably transfecting LNCaP cells with BCL2 antisense (BCL2-AS) transcript-expressing plasmids. Western blotting analysis showed that intracellular Bcl2 protein was decreased by 50-60% in BCL2-AS-transfected LNCaP cells. Expression of the antisense transcripts resulted in 50% growth inhibition of LNCaP cells in response to androgen withdrawal and markedly sensitized these cells to Adriamycin-induced apoptosis. These results suggest that down-regulation of Bcl2 protein using BCL2-AS transcripts could be exploited for improved treatment of advanced CaP.

AB - Prostate cancer (CaP) is the most commonly diagnosed cancer of aging men and the second leading cause of male cancer death in the United States. At present, no effective therapy is available for treating hormone independent CaP. Since Bcl2 is believed to play a role in protecting CaP cells from apoptosis, we investigated the effects of down-regulating Bcl2 expression on CaP cells. Genetically engineered LNCaP sublines were established by stably transfecting LNCaP cells with BCL2 antisense (BCL2-AS) transcript-expressing plasmids. Western blotting analysis showed that intracellular Bcl2 protein was decreased by 50-60% in BCL2-AS-transfected LNCaP cells. Expression of the antisense transcripts resulted in 50% growth inhibition of LNCaP cells in response to androgen withdrawal and markedly sensitized these cells to Adriamycin-induced apoptosis. These results suggest that down-regulation of Bcl2 protein using BCL2-AS transcripts could be exploited for improved treatment of advanced CaP.

KW - Apoptosis

KW - Bcl2

KW - BCL2-AS

KW - LNCaP

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0035217928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035217928&partnerID=8YFLogxK

M3 - Article

C2 - 11776759

AN - SCOPUS:0035217928

VL - 16

SP - 421

EP - 429

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 5

ER -